DXCM DexCom, Inc.
DXCM DexCom, Inc.
Healthcare · Medical Devices
Desk view
Market read
Scan convergence 2 scans as of 2026-10-16 2 bull converging
POC $72.55 · VWAP $70.74 · +21.6% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster EVP, Director + 1 other sold $1.1M, Sep 14–16
Coverage
3 watchlists
DXCM Price Structure
Loading timeframes…
Peers
Every watchlist DXCM belongs to, members best 30-day change first — DXCM highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@healthcare-scan
@healthcare
@biotech-scan
Reported the quarter ending 2026-06-30: revenue $1.31B, diluted EPS $0.64, net income $249M (SEC filing). Across the print the stock moved +11.1% (close before → first close after).
full note →Against street estimates
How DXCM's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
DXCM research tape
86 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.